Advertisement
A vs RVTY
Which Stock Would AI Choose? Agilent Technologies (A) vs. Revvity (RVTY) Stock Comparison
Key Takeaways
- Agilent Technologies (A) has delivered stronger year-to-date performance compared with Revvity (RVTY), with a YTD return of approximately 15% versus more modest gains for RVTY.
- Both companies operate in the life sciences and diagnostics space, with Agilent emphasizing analytical instrumentation and Revvity focusing on reagents, software, and immunodiagnostics solutions.
- Revvity reported first-quarter 2026 results in early May that featured revenue growth and an earnings beat, while Agilent is scheduled to release its second-quarter fiscal 2026 results on May 27.
- Analyst consensus ratings remain Buy for both stocks, with price targets implying notable upside potential from recent closing levels near $115 for A and $97 for RVTY.
- Recent market activity has highlighted Agilent’s order momentum in clinical applications and Revvity’s portfolio optimization efforts amid softer near-term growth expectations.
- Sector exposure overlaps in healthcare and life sciences, though relative performance and upcoming catalysts create distinct positioning for traders monitoring momentum and stability.
Introduction
Agilent Technologies (A) and Revvity (RVTY) represent two established players in the life sciences sector, offering investors exposure to analytical tools, diagnostics, and related technologies. This comparison examines their recent performance, business profiles, and market positioning to assist traders and investors evaluating relative opportunities in healthcare instrumentation and reagents. The analysis draws on observable price behavior, earnings trends, and sector dynamics from the past several weeks, providing context for those seeking balanced insights into these names without favoring one over the other.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies provides analytical instrumentation, software, and services across life sciences, diagnostics, and applied markets. In recent weeks, the stock has shown resilience, trading near $115 as of late May 2026 and posting a year-to-date return exceeding the broader market benchmark. Positive order trends, including growth in the clinical business and a book-to-bill ratio above 1.0x, have supported sentiment following the first-quarter fiscal 2026 report. Upcoming second-quarter results scheduled for May 27 represent a near-term catalyst, while analyst targets cluster around $163, reflecting expectations tied to expansion in biopharmaceutical and diagnostics end markets. Broader market activity has favored stability in Agilent’s diversified portfolio amid fluctuating sector conditions.
Revvity (RVTY) Overview and Recent Performance
Revvity delivers reagents, instruments, software, and services primarily for life sciences and diagnostics applications, including immunodiagnostics. The stock has traded around $97 in recent sessions, with performance reflecting mixed signals after the first-quarter 2026 earnings release in early May. Revenue rose 9.3% year-over-year to $687 million, accompanied by an adjusted earnings per share beat, though full-year organic growth guidance of 3-4% tempered some enthusiasm. Portfolio adjustments and planned divestitures have influenced positioning, while recent share-price fluctuations highlight sensitivity to growth outlook revisions. Analyst price targets average near $107, consistent with ongoing interest in the company’s life-sciences exposure.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots designed for current market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only the highest-performing and most suitable bots for prevailing trends earn placement in this section. Available bots span a wide range of trading styles, strategies, timeframes, and performance statistics, with historical win rates and returns varying significantly across the platform. This diversity allows users to explore automated approaches tailored to specific market environments. For additional details on the full suite of options, visit the Trending AI Robots page.
Head-to-Head Comparison
Agilent Technologies and Revvity both serve overlapping life-sciences and diagnostics customers yet differ in business emphasis: Agilent centers on high-precision analytical instruments and services, while Revvity prioritizes reagents, software platforms, and immunodiagnostics workflows. Growth drivers for Agilent include recent order acceleration in clinical segments; Revvity’s trajectory reflects portfolio pruning and measured organic expansion targets of 3-4% for 2026. Recent momentum has tilted toward Agilent on a year-to-date basis, whereas Revvity’s post-earnings reaction illustrated greater volatility around guidance. Risk factors include sector-wide demand fluctuations for both, with Agilent benefiting from broader end-market resilience and Revvity navigating specific divestiture plans. Market sentiment remains constructive on analyst ratings for each, though relative positioning favors stability metrics at Agilent versus targeted optimization at Revvity.
Tickeron AI Verdict
Based on observable trend consistency, order momentum, and relative positioning in recent market activity, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term characteristics to Agilent Technologies (A) over Revvity (RVTY). This assessment rests on stronger year-to-date performance alignment and upcoming earnings visibility rather than definitive forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and RVTY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileRVTY’s FA Score has 2 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- RVTY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while RVTY’s TA Score has 3 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 6 bearish.
- RVTY’s TA Score: 3 bullish, 6 bearish.
Price Growth
A (@Medical Specialties) experienced а -4.13% price change this week, while RVTY (@Medical Specialties) price change was +1.31% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | RVTY | A / RVTY | |
| Capitalization | 36.7B | 11.1B | 331% |
| EBITDA | 1.96B | 773M | 254% |
| Gain YTD | -4.190 | 3.151 | -133% |
| P/E Ratio | 26.07 | 47.91 | 54% |
| Revenue | 7.23B | 2.9B | 249% |
| Total Cash | 1.81B | 860M | 210% |
| Total Debt | 3.36B | 3.35B | 100% |
A | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 95 | 100 | |
SMR RATING 1..100 | 44 | 89 | |
PRICE GROWTH RATING 1..100 | 46 | 49 | |
P/E GROWTH RATING 1..100 | 63 | 32 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is in the same range as RVTY (15) in the Medical Specialties industry. This means that A’s stock grew similarly to RVTY’s over the last 12 months.
A's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as RVTY (100) in the Medical Specialties industry. This means that A’s stock grew similarly to RVTY’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for RVTY (89) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than RVTY’s over the last 12 months.
A's Price Growth Rating (46) in the Biotechnology industry is in the same range as RVTY (49) in the Medical Specialties industry. This means that A’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's P/E Growth Rating (32) in the Medical Specialties industry is in the same range as A (63) in the Biotechnology industry. This means that RVTY’s stock grew similarly to A’s over the last 12 months.
| A | RVTY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 70% | 3 days ago 77% |
| Stochastic ODDS (%) | 3 days ago 56% | 3 days ago 69% |
| Momentum ODDS (%) | 3 days ago 58% | 3 days ago 72% |
| MACD ODDS (%) | 3 days ago 64% | 3 days ago 74% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 65% |
| TrendMonth ODDS (%) | 3 days ago 58% | 3 days ago 60% |
| Advances ODDS (%) | 11 days ago 60% | 6 days ago 66% |
| Declines ODDS (%) | 4 days ago 62% | 13 days ago 67% |
| BollingerBands ODDS (%) | 3 days ago 66% | 3 days ago 71% |
| Aroon ODDS (%) | 3 days ago 69% | 3 days ago 52% |
Advertisement
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | -1.83% | ||
| TMO - RVTY | 70% Closely correlated | -1.33% | ||
| IQV - RVTY | 66% Loosely correlated | +0.22% | ||
| A - RVTY | 65% Loosely correlated | +0.22% | ||
| CRL - RVTY | 65% Loosely correlated | -0.29% | ||
| DHR - RVTY | 64% Loosely correlated | -0.38% | ||
More | ||||